Based on the NeoGenomics Inc stock forecast from 8 analysts, the average analyst target price for NeoGenomics Inc is USD 18.46 over the next 12 months. NeoGenomics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of NeoGenomics Inc is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, NeoGenomics Inc’s stock price was USD 9.09. NeoGenomics Inc’s stock price has changed by -5.17% over the past week, -32.75% over the past month and -42.97% over the last year.
No recent analyst target price found for NeoGenomics Inc
No recent average analyst rating found for NeoGenomics Inc
Company Overview NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. Read Less
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, onco...Read More
Frequently Asked Questions About NeoGenomics Inc (NEO) Stock
Based on ratings from 8 analysts NeoGenomics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on NEO's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for NEO is USD 18.46 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 16.
NEO stock's Price/Earning ratio is 9.01.
Our analysis grades NEO stock's Price / Earning ratio at C-. This means that NEO stock's Price/Earning ratio is above 29% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this NEO may be undervalued for its sector.
The last closing price of NEO's stock was USD 9.09.
The most recent market capitalization for NEO is USD 1.85B.
Based on targets from 8 analysts, the average taret price for NEO is projected at USD 18.46 over the next 12 months.
This means that NEO's stock price may go up by +103.21% over the next 12 months.
We can't find any ETFs which contains NeoGenomics Inc's stock.
As per our most recent records NeoGenomics Inc has 2,100 Employees.
NeoGenomics Inc's registered address is 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912.
You can get more information about it from NeoGenomics Inc's website at https://www.neogenomics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About NeoGenomics Inc (NEO) Stock
Based on ratings from 8 analysts NeoGenomics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on NEO's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for NEO is USD 18.46 over the next 12 months. The maximum analyst target price is USD 22 while the minimum anlayst target price is USD 16.
NEO stock's Price/Earning ratio is 9.01.
Our analysis grades NEO stock's Price / Earning ratio at C-. This means that NEO stock's Price/Earning ratio is above 29% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this NEO may be undervalued for its sector.
The last closing price of NEO's stock was USD 9.09.
The most recent market capitalization for NEO is USD 1.85B.
Based on targets from 8 analysts, the average taret price for NEO is projected at USD 18.46 over the next 12 months.
This means that NEO's stock price may go up by +103.21% over the next 12 months.
We can't find any ETFs which contains NeoGenomics Inc's stock.
As per our most recent records NeoGenomics Inc has 2,100 Employees.
NeoGenomics Inc's registered address is 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912.
You can get more information about it from NeoGenomics Inc's website at https://www.neogenomics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NEO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
